Merck makes the case for PAH drug Winrevair in patients with earlier disease

Merck's pulmonary arterial hypertension drug Winrevair cut the risk of “clinical worsening” — an endpoint made up of a variety of signs showing that a patient's illness is progressing — by 76% in recently diagnosed patients. ...